180 related articles for article (PubMed ID: 18701498)
1. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.
Varela JC; Imai M; Atkinson C; Ohta R; Rapisardo M; Tomlinson S
Cancer Res; 2008 Aug; 68(16):6734-42. PubMed ID: 18701498
[TBL] [Abstract][Full Text] [Related]
2. Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity.
Caragine TA; Imai M; Frey AB; Tomlinson S
Blood; 2002 Nov; 100(9):3304-10. PubMed ID: 12384431
[TBL] [Abstract][Full Text] [Related]
3. Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells.
Fernández-Centeno E; de Ojeda G; Rojo JM; Portolés P
J Immunol; 2000 May; 164(9):4533-42. PubMed ID: 10779754
[TBL] [Abstract][Full Text] [Related]
4. Complement-dependent T-cell lymphopenia caused by thymocyte deletion of the membrane complement regulator Crry.
Miwa T; Zhou L; Kimura Y; Kim D; Bhandoola A; Song WC
Blood; 2009 Mar; 113(12):2684-94. PubMed ID: 19136662
[TBL] [Abstract][Full Text] [Related]
5. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
6. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
[TBL] [Abstract][Full Text] [Related]
7. Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack.
Barata L; Miwa T; Sato S; Kim D; Mohammed I; Song WC
J Immunol; 2013 Mar; 190(6):2886-95. PubMed ID: 23390291
[TBL] [Abstract][Full Text] [Related]
8. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
9. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury.
Miao J; Lesher AM; Miwa T; Sato S; Gullipalli D; Song WC
Kidney Int; 2014 Oct; 86(4):726-37. PubMed ID: 24850152
[TBL] [Abstract][Full Text] [Related]
11. Mesangial cell complement receptor 1-related protein y limits complement-dependent neutrophil accumulation in immune complex glomerulonephritis.
Bao L; Wang Y; Chen P; Sarav M; Haas M; Minto AW; Petkova M; Quigg RJ
Immunology; 2009 Sep; 128(1 Suppl):e895-904. PubMed ID: 19740350
[TBL] [Abstract][Full Text] [Related]
12. Membrane protein Crry maintains homeostasis of the complement system.
Wu X; Spitzer D; Mao D; Peng SL; Molina H; Atkinson JP
J Immunol; 2008 Aug; 181(4):2732-40. PubMed ID: 18684964
[TBL] [Abstract][Full Text] [Related]
13. The murine complement regulator Crry: new insights into the immunobiology of complement regulation.
Molina H
Cell Mol Life Sci; 2002 Feb; 59(2):220-9. PubMed ID: 11915940
[TBL] [Abstract][Full Text] [Related]
14. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity.
Miwa T; Zhou L; Tudoran R; Lambris JD; Madaio MP; Nangaku M; Molina H; Song WC
Mol Immunol; 2007 Jan; 44(1-3):139-46. PubMed ID: 16887189
[TBL] [Abstract][Full Text] [Related]
15. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells.
Renner B; Coleman K; Goldberg R; Amura C; Holland-Neidermyer A; Pierce K; Orth HN; Molina H; Ferreira VP; Cortes C; Pangburn MK; Holers VM; Thurman JM
J Immunol; 2010 Sep; 185(5):3086-94. PubMed ID: 20675597
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
[TBL] [Abstract][Full Text] [Related]
17. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.
Song H; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2007 Dec; 179(11):7860-7. PubMed ID: 18025232
[TBL] [Abstract][Full Text] [Related]
18. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
Zhang X; Shi X; Li J; Hu Z; Guo F; Huang X; Zhang Z; Sun P; Jing Y; Gao J; Tan W
Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685
[TBL] [Abstract][Full Text] [Related]
19. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y.
Banda NK; Kraus DM; Muggli M; Bendele A; Holers VM; Arend WP
J Immunol; 2003 Aug; 171(4):2109-15. PubMed ID: 12902517
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model.
Gelderman KA; Kuppen PJ; Okada N; Fleuren GJ; Gorter A
Cancer Res; 2004 Jun; 64(12):4366-72. PubMed ID: 15205353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
